Using Mass Spectrometry as a Tool. Emergencies
|
|
- Madeleine Eaton
- 6 years ago
- Views:
Transcription
1 United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Rapid, Sensitive Dose Assessment Using Mass Spectrometry as a Tool to Identify Markers for Public Health Emergencies Lynne K. Wathen, PhD Division of CBRN Countermeasures Biomedical Advanced Research and Development e e Authority ty April 19, th Annual Oak Ridge Conference Emerging Technologies for 21 st Century Diagnostics San José, California
2 Biomedical Advanced Research and Development Authority (BARDA) Mission Ensuring the availability of medical countermeasures and diagnostic tools to address public health emergencies Three threat areas: Chem/Bio/Rad/Nuc, Pandemic Influenza, Emerging Infectious Diseases Comprehensive portfolio approach to development and acquisition of products Unique niche in USG biomedical R&D Bridge the Valley of Death Mid- to late-stage product development Work with industry to progress product candidates through the pipeline ASPR: Resilient People. Healthy Communities. A Nation Prepared.
3 Public Health Emergency Medical Countermeasures Enterprise National Biodefense Science Board NIH BARDA BARDA and CDC BARDA and CDC CDC and ASPR/OPEO Research and Development Advanced Development Acquisition FDA Storage/ Maintenance Deployment Utilization PHEMCE COORDINATED PLANNING & EXECUTION Ex Officio Members: ASPR: Resilient People. Healthy Communities. A Nation Prepared. 3
4 Spectrum of Radiation Health Effects ASPR: Resilient People. Healthy Communities. A Nation Prepared. 4
5 Biodosimetry Concepts of Operation Event Days Million People to Screen <2 Gy Testing with POC Device > 2 Gy? 2 Gy High Through- Put Dosimetry and Additional Screening Therapeutic Administrations Follow-on Care Evacuate Area ASPR: Resilient People. Healthy Communities. A Nation Prepared. 5
6 Current Biodosimetry Capabilities Radiation Dose Assessment Tools Victim s location relative to incident Signs and Symptoms Blood Cell Counts Laboratory-based Cytogenetics Deficiency Provides only a rough estimate false positive rate Requires two blood draws separated by days and the ability to connect data Dicentric Chromosome Assay takes 2-3 days for result and few laboratories offer the test ASPR: Resilient People. Healthy Communities. A Nation Prepared. 6
7 Current BARDA Biodosimetry Program Contractors Point of Care TECHNOLOGY (POC) or High Through-put (HT) Protein DNA mrna Volatile Organic Compounds Ocular Electron Paramagnetic Resonance Contractor 1 Both Contractor 2 HT Contractor 3 POC Contractor 4 HT Contractor 5 HT Contractor 6 POC Contractor 7 POC Contractor 8 POC ASPR: Resilient People. Healthy Communities. A Nation Prepared.
8 Example of One Contractor s Approach Using Mass Spectrometry as a Tool for Identifying Biodosimetry Markers of Interest ASPR: Resilient People. Healthy Communities. A Nation Prepared. 8
9 Example Project Methodology Animal Studies Mouse in vivo IR Human RT Patients Sample Analysis LC-MS/MS Analysis Protein Change List ELISA Analysis Data Analysis Regression Models Cluster Analysis Linear Disc. Analysis Tree Based Classifiers Candidate Biomarkers Candidate Markers (Mouse) Protein 1 Protein 2 Protein 3 Selection Criteria Fold Change Natural & CF variability Predictive Sensitive & specific assays Different pathways Candidate Markers (Human) Protein 4 Protein 5 Protein 6 Final Biomarkers Validated Markers Protein 1 Protein 2 Protein 3 Protein 4 Protein 5 Protein 6 ASPR: Resilient People. Healthy Communities. A Nation Prepared. 9
10 Complex Mixture of Proteins Example LC-MS/MS Approach for Protein Identification digestion A L E L F R H H K P N D M A A K G A S E D I P V K D H L K L K F G G H P E T L E D E S E M K H K A F D K K D K H L K K S A L F K V Y K Q E L F K L Q I P V K A L D V A GM HM K G I G W GG V Q G A A L E L F R E E G V E L G V Q F Q G L N G M I I S E D E M K K M R L L S Separation G L V S D G E W Q L F D F K K A I K N D M A A K L T A E A S E D L K V H T H G H E A E L T P L A Q S H A T S K by HPLC N G I E L G F Q G Y L E F G H P E T L E K Peptide digest K Y K F K H P G D F G A D A Q G A M S K V E A D V A G H G Q E V L I R Y L E F I S E A I I Q V L Q S K G H H E A E L T P A Q S H A T K M G L S D G E W Q L V L N V W G K On-line analysis by OrbiTrap MS Spectrum Database search Protein ID ASPR: Resilient People. Healthy Communities. A Nation Prepared. MS/MS Spectrum 10
11 Protein 1 LC-MS/MS Results E E L E L L V S S L R A Q V E S F R 6 Gy, Day 5 6 Gy, Day 5 0 Gy, Day 5 0 Gy, Day 5 E F W L G L D N L S K 6 Gy, Day 5 0 Gy, Day 5 centration (ng/ml) Protein 1 Con ELISA Results 0 & 6 Gy, Day Gy 6 Gy Dose (Gy) Demonstrated Correlation Between LC-MS/MS Analysis on Pooled Samples ASPR: and ELISA Resilient Analysis People. Healthy on Individual Communities. Samples A Nation Prepared. 11
12 Example Project Plan Focused on Product Development Initial Year Second Year Third Year Fourth Year Product Development 180 candidate mass peaks 36 identified proteins 6 marker panel Human panel Mass peaks Key radiation Predictive Predictive e Complete human only no protein ID Good classifiers with 5-10 peaks responsive proteins identified ELISA confirmation of mouse marker panel Tested against 4 potentially confounding marker panel Alpha Instrument Development validation in irradiated patients Beta Testing Complete mass spec. conditions FDA filing data ASPR: Resilient People. Healthy Communities. A Nation Prepared. 12
13 Scatter Plots to Separate Irradiated versus Non-irradiated Mice Non Irradiated Irradiated (ng/ml) Protein 1 Conc false negatives out of 298 samples (0.67% Fn) 1 false positive out of 298 samples (0.34% Fp) Protein 2 Conc (ng/ml) Protein 1 alone results in 99% Correct classification of non-irradiated from irradiated ASPR: Resilient People. Healthy Communities. A Nation Prepared. 13
14 Additional Proteins are Necessary for < and 6 Gy in Mice Protein 1 Conc (ng/ml) <6 Gy >6 Gy Scatter plot of Protein 1 and Protein 2 results in 87% correct classification <6 Gy from 6 Gy 0 false negatives out of 298 samples(00%fn) (0.0% 38 false positive out of 298 samples (12.8% Fp) All false positive samples are 4 Gy classified as 6Gy Protein 2 Conc (ng/ml) Additional Proteins and More Sophisticated Models are Needed to Separate and < 6 Gy ASPR: Resilient People. Healthy Communities. A Nation Prepared. 14
15 Human Radiotherapy Patient Panel The three most important radiation responsive proteins in the panel include Protein 4 (up-regulated) Protein 5 (down-regulated) Protein 6 (up-regulated in TBI patients) Two of these proteins are used in the mouse panel Tree classifiers using these three proteins can distinguish irradiated patients from controls with 96% accuracy Data provides positive indication that plasma protein biodosimetry is feasible in humans requires NHP study to expand panel and confirm 0 tion (ng/ml) Plasma Concentrat Plasma Co oncentration (ng/ml) Concentration (ng/ml) Plasma Protein 4 Controls Infection Trauma TBI(d0) TBI(d1) TBI(d2) TBI(d3) Sample Group Protein 6 Controls RT(d0) RT(d1) RT(d2) RT(d3) Sample Group Protein 5 Controls RT(d0) RT(d1) RT(d2) RT(d3) Sample Group ASPR: Resilient People. Healthy Communities. A Nation Prepared. 15
16 Example Summary and Conclusions Using LC-MS/MS techniques identified 180 mass peaks for interigation The LC-MS/MS Approach identified 36 Radiation-responsive proteins in the mouse model A subset of these proteins have been confirmed in mouse plasma using ELISA Using 6 proteins from this panel correctly classifies all large-scale l mouse data sets Two groups (< 6 Gy or 6 Gy) with low false negative (FN) and false positive (FP) rates The LC-MS/MS Approach identified 8 Radiation-responsive proteins in human radiotherapy patient samples Preliminary panels of 3 proteins can easily distinguish between irradiated patients and controls ASPR: Resilient People. Healthy Communities. A Nation Prepared. 16
17 Areas of Interest for Contractors in Diagnostic Development A pre-proposal conference is planned to on Thursday, May 3, 2012, from 2:00pm to 4:00pm provide details regarding the following potential Broad Agency Announcements (BAAs): BARDA-CBRN-BAA SOL-00011, entitled Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures ; BARDA-SST-BAA SOL-00013, entitled Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development, and; BARDA-FLU-BAA , entitled Advanced Development of Medical Countermeasures for Pandemic Influenza. To register for the conference, please the name of your company, as well as the names and *citizenship of registrants to AMCG-Opportunities@hhs.gov by 3:00 PM EDT Tuesday, May 1, ASPR: Resilient People. Healthy Communities. A Nation Prepared. 17
18 Interfacing with BARDA Portal to BARDA Register, request a meeting Tech Watch presentation Official announcements and detailed information about all government contract solicitations See presolicitation announcement: a1eaed051a0223ffd180b5cbe&tab=core&_cview=1 ASPR: Resilient People. Healthy Communities. A Nation Prepared.
Biodosimetry: An HHS Priority for Radiological Public Health Emergencies
Biodosimetry: An HHS Priority for Radiological Public Health Emergencies Biomedical Advanced Research and Development Authority (BARDA) Donna S. Boston Project Officer HHS/ASPR/BARDA National Radiological
More informationNATIONAL PRIORITIES:
NATIONAL PRIORITIES: CONTINUOUS MANUFACTURING OF MEDICAL COUNTERMEASURES R. Thomas Warf, Director Manufacturing, Facilities, and Engineering HHS/ASPR/BARDA June 27, 2016 Resilient People. Healthy Communities.
More informationUNCLASSIFIED. FY 2016 Base
Exhibit R-2, RDT&E Budget Item Justification: PB 2016 Defense Health Program Date: February 2015 0130: Defense Health Program / BA 2: RDT&E COST ($ in Millions) Prior Years FY 2014 FY 2015 Base OCO Total
More informationCDRH: Advancing Regulatory Science. Murray Malin, MD Center for Devices and Radiological Health March 29, 2011
CDRH: Advancing Regulatory Science Murray Malin, MD Center for Devices and Radiological Health March 29, 2011 Medical Countermeasures Diagnostic and Detection Devices Personal Protective Equipment (PPE)
More informationQLD BioBriefing / BioCheers - September Medical Countermeasures. Overview and Funding opportunities. Felicia Pradera - PLMCM
QLD BioBriefing / BioCheers - September 2018 Medical Countermeasures Overview and Funding opportunities Capability through collaboration Felicia Pradera - PLMCM DMTC Overview 2 Vision: DMTC Operational
More informationDISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011
DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS September, 2011 1 CAPRION PROTEOMICS Leading proteomics-based service provider - Biomarker and target discovery
More informationBiodefense and Infectious Diseases Funding Opportunities
FreeMindGroup FreeMind Group @FreeMindGrp Biodefense and Infectious Diseases Funding Opportunities Jonathan Adalist Senior Director, Business Development FreeMind Group FreeMind Group, LLC FreeMind Group
More informationMedical Device Non-Dilutive Funding: Trends & Opportunities
FreeMindGroup FreeMind Group @FreeMindGrp Medical Device Non-Dilutive Funding: Trends & Opportunities B. Stuart Jacobowitz Sr. Director, Business Development December 6, 2017 FreeMind Group FreeMind Group,
More informationContinuing Continuing
COST(In Millions) FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 Cost to Total Cost Complete Total Program Element (PE) 2.109 1.996 2.043 2.075 2.115 2.154 2.200 Continuing Continuing Cost Risk
More informationNational Defense Industrial Association Armed Services Biomedical Research Evaluation and Management March 2018
National Defense Industrial Association Armed Services Biomedical Research Evaluation and Management 20-22 March 2018 RDML Mary Riggs Director, Defense Health Agency Research Directorate Chair, ASBREM
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationNIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program
NIH/NIAID Radiation/Nuclear Medical Countermeasures Development Program Bert W. Maidment, Ph.D. Associate Director for Product Development Division of Allergy, Immunology, and Transplantation National
More informationBIODOS - Biodosimetry application in emergency preparedness BIOPEX - Emergency preparedness exercise for biological dosimetry
BIODOS - Biodosimetry application in emergency preparedness BIOPEX - Emergency preparedness exercise for biological dosimetry Carita Lindholm - Radiation and Nuclear Safety Authority (STUK) Daniela Stricklin
More informationMedical Countermeasures to Chemical and Biological Threats
Medical Countermeasures to Chemical and Biological Threats Mission The U.S. Army Medical Research and Materiel Command s (USAMRMC s) mission is to provide medical knowledge and materiel life-cycle management
More informationNIAID Resources to Facilitate Medical Countermeasure Development
NIAID Resources to Facilitate Medical Countermeasure Development Paula Bryant, Ph.D. Senior Scientific Officer Concept Acceleration Program Biodefense, Research Resources, and Translational Research (OBRRTR)
More informationMedicinal Chemistry of Modern Antibiotics
Chemistry 259 Medicinal Chemistry of Modern Antibiotics Spring 2012 Lecture 5: Modern Target Discovery & MOA Thomas Hermann Department of Chemistry & Biochemistry University of California, San Diego Drug
More informationMedicinal Chemistry of Modern Antibiotics
Chemistry 259 Medicinal Chemistry of Modern Antibiotics Spring 2008 Lecture 5: Modern Target Discovery & MOA Thomas Hermann Department of Chemistry & Biochemistry University of California, San Diego Drug
More informationCommercial Challenges: Perspectives from the Biotechnology Industry
Commercial Challenges: Perspectives from the Biotechnology Industry Eric A. Rose CEO and Chairman, SIGA Technologies; Guggenheim Professor and Chair Dept. of Health Evidence and Policy Mount Sinai School
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationStrategies for Quantitative Proteomics. Atelier "Protéomique Quantitative" La Grande Motte, France - June 26, 2007
Strategies for Quantitative Proteomics Atelier "Protéomique Quantitative", France - June 26, 2007 Bruno Domon, Ph.D. Institut of Molecular Systems Biology ETH Zurich Zürich, Switzerland OUTLINE Introduction
More informationResearch Powered by Agilent s GeneSpring
Research Powered by Agilent s GeneSpring Agilent Technologies, Inc. Carolina Livi, Bioinformatics Segment Manager Research Powered by GeneSpring Topics GeneSpring (GS) platform New features in GS 13 What
More informationThe Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products
The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products Jay S. Epstein, M.D. CBER, FDA Biologicals are Complex Products Critical
More informationASSOCIATION OF STATE AND TERRITORIAL HEALTH OFFICIALS
June 19, 2018 Chairman Michael Burgess Energy & Commerce Health Subcommittee Washington, D.C. 20515 Ranking Member Gene Green Energy & Commerce Health Subcommittee Washington, D.C. 20515 Dear Chairman
More informationDIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE
DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE EXECUTIVE SUMMARY Oncologists reviewing blood and tissue test results face the same problems: Is the
More informationBlue Ribbon Study Panel on Biodefense Medical Countermeasure Reform Page 1
Blue Ribbon Study Panel on Biodefense Medical Countermeasure Reform Page 1 May 4, 2018 Chairman Greg Walden Ranking Member Frank Pallone, Jr. Committee on Energy and Commerce Committee on Energy and Commerce
More informationImproving the Limit of Detection of Lateral Flow Assays using 3DNA Technology
Improving the Limit of Detection of Lateral Flow Assays using 3DNA Technology Introduction Lateral Flow (LF) and similar assays represent a unique growing class of Point of Care (POC) tests designed to
More informationCLSI C60: Assay Validation & Post-Validation Monitoring
CLSI C60: Assay Validation & Post-Validation Monitoring Ross J. Molinaro, MT(ASCP), PhD, DABCC, FACB Medical Director Core Laboratory, Emory University Hospital Midtown Emory Clinical Translational Research
More informationIncreasing Throughput and Efficiency with Exactive LC/MS and Triple Quadrupole LC/MS/MS
Increasing Throughput and Efficiency with Exactive LC/MS and Triple Quadrupole LC/MS/MS Nicholas Duczak Thermo Scientific Annual Mass Spectrometry Users Meeting Somerset, NJ October 12th, 2011 Lead Finding
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationNone related to this presentation
None related to this presentation 2 University of Minnesota Dr. Gary Nelsestuen Dr. Christ Wendt Harvard Medical School Dr. Nader Rifai Dr. Mark Kellogg University of Rochester Medical Center Dr. Bruce
More informationOraSure Technologies Jefferies 2016 Healthcare Conference
OraSure Technologies Jefferies 2016 Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forwardlooking statements, including statements with respect
More informationWelcome! Making the case for advancing the Exposome (or EWAS)
Welcome! Making the case for advancing the Exposome (or EWAS) David M. Balshaw, Ph.D. Program Administrator Center for Risk and Integrated Sciences National Institute of Environmental Health Sciences Environmental
More informationCapabilities & Services
Capabilities & Services Accelerating Research & Development Table of Contents Introduction to DHMRI 3 Services and Capabilites: Genomics 4 Proteomics & Protein Characterization 5 Metabolomics 6 In Vitro
More informationFacilitating Antibacterial Drug Development Outlining the Path Forward
Facilitating Antibacterial Drug Development Outlining the Path Forward Helen Boucher, MD FIDSA FACP Division of Infectious Diseases and Geographic Medicine Tufts Medical Center Tufts University School
More informationNon-Dilutive Funding for Opportunities for CNS/PNS Related R&D
FreeMindGroup FreeMind Group @FreeMindGrp Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D Jonathan H. Adalist Sr. Director, Business Development September 6, 2017 FreeMind Group FreeMind
More informationDevelopment of an Immunoprecipitation and LC-MS/MS based Method for Quantifying the 105 kda Recombinant Protein SXN in Plasma.
Development of an Immunoprecipitation and LC-MS/MS based Method for Quantifying the 105 kda Recombinant Protein SXN101959 in Plasma. Richard Kay Principal Scientist, Bioanalytical Sciences, Quotient Bioresearch
More informationFDA Perspectives on Novel Kidney Biomarker Tests
FDA Perspectives on Novel Kidney Biomarker Tests 2013 Arnold O. Beckman Conference Novel Biomarkers of Kidney Disease: False Dawn or New Horizon? November 5-6, 2013 Courtney H. Lias, Ph.D. Office of In
More informationMany thanks to: An update on radiological and nuclear terrorism. Threats. Nuclear Terrorism. Nuclear devices. Radiological versus physical deaths
An update on radiological and nuclear terrorism P. Andrew Karam, Ph.D., CHP Research Assistant Professor Rochester Institute of Technology Many thanks to: Ron L and the NOCHPS for inviting me to this meeting
More informationIntroduction to Proteomics
Introduction to Proteomics Tasso Miliotis, PhD AstraZeneca R&D Gothenburg Translational Sciences tasso.miliotis@astrazeneca.com 1 Site Management Mölndal May 2008 Outline Drug Discovery AZ R&D Sample Preparation
More informationThe Direction of Thermo Fisher Scientific
The Direction of Thermo Fisher Scientific Iain Mylchreest Ph.D, VP GM Life Sciences MS Thermo Scientific Mass Spectrometry Users Meeting Indianapolis September 22 th, 2011 The World Leader in Serving Science
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationAuthorization of Emergency Use of an In Vitro Diagnostic Device for Diagnosis of Zika Virus
This document is scheduled to be published in the Federal Register on 03/28/2016 and available online at http://federalregister.gov/a/2016-06888, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationThe Future of Reimbursement for Lab Developed Mass Spec Assays
The Future of Reimbursement for Lab Developed Mass Spec Assays Charles Root, PhD CodeMap, LLC Schaumberg, IL AACC/MSSS Mass Spectrometry and Separation Sciences for Lab Medicine Oct 1 2, 2015 1 The Future
More informationPhase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation
Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis,
More informationJoint Project Manager Transformational Medical Technologies Advanced Planning Briefing for Industry
Joint Project Manager Transformational Medical Technologies Advanced Planning Briefing for Industry September 7, 2011 Protecting the Warfighter and the Nation from Biothreats. MR. DAVID E. HOUGH Joint
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationNanosensor biodosimetry of mouse blood proteins after exposure to ionizing radiation
Supplementary Information Nanosensor biodosimetry of mouse blood proteins after exposure to ionizing radiation Dokyoon Kim, Francesco Marchetti 8,9, Zuxiong Chen, Sasa Zaric, Robert J. Wilson, Drew A.
More informationAdvancing Regulatory Science at the US Food and Drug Administration
Advancing Regulatory Science at the US Food and Drug Administration US Food and Drug Administration EPAA Annual Conference Brussels 9 November 2011 1 Suzanne C. Fitzpatrick, PhD, DABT Senior Science Advisor
More informationABERDEEN PROVING GROUND ADVANCED PLANNING BRIEFING TO INDUSTRY
UNCLASSIFIED//FOUO ABERDEEN PROVING GROUND ADVANCED PLANNING BRIEFING TO INDUSTRY 1 U.S. Army Medical Research Institute of Chemical Defense MAJ Mariano Mesngon, Deputy Chief for Science Program Analysis
More informationProMass HR Applications!
ProMass HR Applications! ProMass HR Features Ø ProMass HR includes features for high resolution data processing. Ø ProMass HR includes the standard ProMass deconvolution algorithm as well as the full Positive
More informationETLS Validation & Verification University of St. Thomas. John Engelman Fall 2016
ETLS 509 - Validation & Verification University of St. Thomas John Engelman Fall 2016 ETLS 509 - Session 3 Review Validation process Verification process Example verification matrix (a small portion) Boeing
More informationA Highly Accurate Mass Profiling Approach to Protein Biomarker Discovery Using HPLC-Chip/ MS-Enabled ESI-TOF MS
Application Note PROTEOMICS METABOLOMICS GENOMICS INFORMATICS GLYILEVALCYSGLUGLNALASERLEUASPARG CYSVALLYSPROLYSPHETYRTHRLEUHISLYS A Highly Accurate Mass Profiling Approach to Protein Biomarker Discovery
More informationNational Reference Centre for Parasitology. Brian Ward &Momar Ndao Colloque Blue 2012
National Reference Centre for Parasitology Brian Ward &Momar Ndao Colloque Blue 2012 Us Why is Diagnostic Testing for Parasites so Complicated? Critical mass of investigators Limited commercial interest
More informationReady, Set, Test! AACC Conference Mass Spectrometry in the Clinical Lab: Best Practice and Current Applications September 17-18, 2013 St.
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationWAIT! Ready, Set, Test! Financial Disclosure. Research/Educational grants/consulting/salary support
Ready, Set, Test! Ross Molinaro, PhD, MLS(ASCP) CM, DABCC, FACB Medical Director, Clinical Laboratories Emory University Hospital Midtown Emory Clinical Translational Research Laboratory AACC Conference
More informationProteomics Background and clinical utility
Proteomics Background and clinical utility H.H. Helgason MD Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute Amsterdam Introduction Background Definitions Protein biomarkers Technical aspects
More informationCell Signaling Technology
Cell Signaling Technology PTMScan Direct: Multipathway v2.0 Proteomics Service Group January 14, 2013 PhosphoScan Deliverables Project Overview Methods PTMScan Direct: Multipathway V2.0 (Tables 1,2) Qualitative
More information2D Liquid-Phase Proteomic Profiling in Pre- Clinical and Mechanistic Analysis of Novel Polynuclear Chemotherapeutics for Glioma
2D Liquid-Phase Proteomic Profiling in Pre- Clinical and Mechanistic Analysis of Novel Polynuclear Chemotherapeutics for Glioma Oliver Bogler, PhD Neurosurgery Problem No good treatment for glioma New
More informationProudly serving laboratories worldwide since 1979 CALL for Refurbished & Certified Lab Equipment
www.ietltd.com Proudly serving laboratories worldwide since 1979 CALL +847.913.0777 for Refurbished & Certified Lab Equipment API 150 EX LC/MS System The API 150EX LC/MS System is the most rugged and reliable
More informationProject BioShield Annual Report
United States Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response Project BioShield Annual Report January 2014 December 2014 Inside front cover blank
More informationJ.P. Morgan Healthcare Conference. Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO
J.P. Morgan Healthcare Conference Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO January 8, 2018 Safe Harbor Statement & Non-GAAP Financial Measures This presentation contains forward-looking
More informationExam MOL3007 Functional Genomics
Faculty of Medicine Department of Cancer Research and Molecular Medicine Exam MOL3007 Functional Genomics Tuesday May 29 th 9.00-13.00 ECTS credits: 7.5 Number of pages (included front-page): 5 Supporting
More information01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical.
Control of Microbial Growth Disinfectants and Antiseptics 1 Methods 2 Three approaches Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical elimination Cleaning Filtration
More informationEnsuring Translational Scientific Understanding Underpins Your Biomarker-Dx Strategy. Thomas Krahn Bayer Pharma AG
Ensuring Translational Scientific Understanding Underpins Your Biomarker-Dx Strategy Thomas Krahn Bayer Pharma AG Forward-Looking Statements / Disclosures This presentation may contain forward-looking
More informationOne Year Later, Where Does the U.S. Response to Ebola Stand?
One Year Later, Where Does the U.S. Response to Ebola Stand? Kaiser Family Foundation, Washington, DC Jen Kates, PhD Vice President & Director, Global Health & HIV Policy Kaiser Family Foundation jkates@kff.org
More informationOrthopaedic Innovation: Bench, Bedside, Bank
Stephen P Makk, MD, MBA A Seth Greenwald, D-Phil (Oxon) Biomedical Engineering Committee American Academy of Orthopaedic Surgeons 1 1 The Patent Process www.uspto.gov 2 2 Patent: A government grant allowing
More informationUniversal Solution for Monoclonal Antibody Quantification in Biological Fluids Using Trap-Elute MicroLC-MS Method
Universal Solution for Monoclonal Antibody Quantification in Biological Fluids Using Trap-Elute MicroLC-MS Method Featuring the SCIEX QTRAP 6500+ LC-MS/MS System with OptiFlow Turbo V source and M5 MicroLC
More informationImmunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals
Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals Daniel Kramer/Kathleen Beach Need for public-private collaboration 1 All biopharmaceuticals are
More informationAccelerating Throughput for Targeted Quantitation of Proteins/Peptides in Biological Samples
Technical Note Accelerating Throughput for Targeted Quantitation of Proteins/Peptides in Biological Samples Biomarker Verification Studies using the QTRAP 5500 Systems and the Reagents Triplex Sahana Mollah,
More informationMETABOLIC PROFILING AND SIGNATURES IN ALS. Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina
METABOLIC PROFILING AND SIGNATURES IN ALS Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina Metabolomics is the newest Omics science DNA Genomics RNA Transcriptomics
More informationMedical Counter Measure Distribution & Dispensing CBERS 2015
Medical Counter Measure Distribution & Dispensing CBERS 2015 Objectives Medical Countermeasures Strategic National Stockpile (SNS) Program Overview Receive Store and Stage (RSS) Sites Points of Dispensing
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationUltra-Sensitive Quantification of Trastuzumab Emtansine in Mouse Plasma using Trap-Elute MicroLC MS Method
Ultra-Sensitive Quantification of Trastuzumab Emtansine in Mouse Plasma using Trap-Elute MicroLC MS Method Featuring SCIEX QTRAP 6500+ System with OptiFlow Turbo V source and M5 MicroLC system Lei Xiong,
More informationSystems Biology and Systems Medicine
CHAPTER 5 Systems Biology and Systems Medicine INTRODUCTION A new approach to biology, termed systems biology, has emerged over the past 15 years or so an approach that looks - - have transformed systems
More informationOptimization-Based Peptide Mass Fingerprinting for Protein Mixture Identification
Optimization-Based Peptide Mass Fingerprinting for Protein Mixture Identification Weichuan Yu, Ph.D. Department of Electronic and Computer Engineering The Hong Kong University of Science and Technology
More informationH.I. Farag 1, A.H. Hashish 2, M.M. Mourad 3, M.M.M. El-Nasharty 1
A Novel Technique Evaluating RIA Analyses Of (Total & Free) And IGF-1 With Respect to ROC And Hartz s OI Performance To Avoid Unnecessary Radiation Exposure to Cancer Prostate Patients H.I. Farag 1, A.H.
More informationPROTÉOMIQUE. Application de la protéomique à la cartographie de l interactome et la découverte de biomarqueurs. BENOIT COULOMBE, PhD
PROTÉOMIQUE Application de la protéomique à la cartographie de l interactome et la découverte de biomarqueurs BENOIT COULOMBE, PhD Laboratoire de protéomique & transcription génique BCM2003, mars 2012
More informationPharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study
Pharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study Featuring the SCIEX BioBA Solution Xi Qu 1, Shuyu Hou 1, Meghan McCann 1, Caroline Becker 1, Xun Wang 1,
More informationGovernment Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER
www.g2gconsulting.com Government Bioscience Grant (GBG) Report October 2016 Title (Agency) Opp. Number Description Deadline Funding Level Eligibility Link BROAD AGENCY ANNOUNCEMENTS 1. Advanced Research
More informationMid-term review. Recitation5 03/31/2014. Stem Cell Biology and Function W4193 1
Mid-term review Recitation5 03/31/2014 Stem Cell Biology and Function W4193 1 What to expect in the midterm2 It will be all so far but mainly whatever was NOT covered by the previous mid-term- not a huge
More informationNIST: Mission, Metrology, and Standards. NBMC Workshop Blood, Sweat, & Tears III November 2-3, 2016
NIST: Mission, Metrology, and Standards NBMC Workshop Blood, Sweat, & Tears III November 2-3, 2016 Peter M. Vallone, Ph.D. Leader, Applied Genetics Group NIST Gaithersburg, MD USA WHY AM I HERE PRECISION
More informationIndividual-Based Correlates of Protection
Module 8 Evaluating Immunological Correlates of Protection Session 3 Evaluating Correlates of Protection Using Individual, Population, and Titer-specific Approaches Ivan S.F. Chan, Ph.D. Merck Research
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationThe U.S. Response to Ebola: Status of the FY2015 Emergency Ebola Appropriation
The U.S. Response to Ebola: Status of the FY2015 Emergency Ebola Appropriation Jen Kates, Josh Michaud, Adam Wexler, and Allison Valentine The Ebola outbreak of 2014 was a global wake-up call regarding
More informationLaura Andrews, PhD, DABT, Fellow ATS
Laura Andrews, PhD, DABT, Fellow ATS What is a Biologic? From PHS Act of 1944 A biologic is any virus, toxin, antitoxin, therapeutic serum, vaccine, blood, blood component or derivative, allergenic products
More informationThe U.S. Response to Ebola: Status of the FY2015 Emergency Ebola Appropriation
November 2015 Issue Brief The U.S. Response to Ebola: Status of the FY2015 Emergency Ebola Appropriation Jen Kates, Josh Michaud, Adam Wexler, and Allison Valentine Overview The Ebola outbreak of 2014
More informationSkyline & Panorama: Key Tools for Establishing a Targeted LC/MS Workflow
Skyline & Panorama: Key Tools for Establishing a Targeted LC/MS Workflow Kristin Wildsmith Scientist, Biomarker Development LabKey User Conference October 6, 2016 Biomarkers enable drug development Drug
More informationLCMS methods and traceability of CSF biomarker measurements
LCMS methods and traceability of CSF biomarker measurements Chiara Giangrande, Gustavo Martos, Amandine Boeuf, Béatrice Lalere, Vincent Delatour chiara.giangrande@lne.fr Reliability of medical tests is
More informationWelcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT
Welcome to the American College of Toxicology s Webinar Series We will begin at 11AM EDT Preparing for Nonclinical edata Regulatory Submissions to the US FDA SEND and Beyond September 5, 2013, 11:00 AM
More informationLTQ Orbitrap XL Hybrid FT Mass Spectrometer Unrivaled Performance and Flexibility
m a s s s p e c t r o m e t r y LTQ Orbitrap XL Hybrid FT Mass Spectrometer Unrivaled Performance and Flexibility Part of Thermo Fisher Scientific LTQ Orbitrap XL OFFERING OUTSTANDING MASS ACCURACY, RESOLVING
More informationBiomarkers for Delirium
Biomarkers for Delirium Simon T. Dillon, Ph. D. Director of Proteomics BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center DF/HCC Proteomics Core Div. of Interdisciplinary Medicine and
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More informationNIAID and Global Health Research Resources for Tuberculosis
NIAID and Global Health Research Resources for Tuberculosis Maria Y. Giovanni, Ph.D. Director, Office of Genomics and Advanced Technologies National Institute of Allergy & Infectious Diseases NIH/DHHS
More informationSpectroDive NEXT GENERATION TARGETED PROTEOMICS. Integration of Ready-Made Panels Improved Workflow for Custom Panels
SpectroDive NEXT GENERATION TARGETED PROTEOMICS Integration of Ready-Made Panels Improved Workflow for Custom Panels IMPROVING MULTIPLEXING FOR TARGETED PROTEOMICS Novel targeted proteomics workflows can
More informationEvidentiary Considerations for Integration of Biomarkers in Drug Development : Statistical Considerations
Evidentiary Considerations for Integration of Biomarkers in Drug Development : Statistical Considerations August 21. 2015 Aloka Chakravarty, PhD Office of Biostatistics, OTS, CDER U.S. Food and Drug Administration
More informationPrimePCR Assay Validation Report
Gene Information Gene Name Gene Symbol Organism Gene Summary Gene Aliases RefSeq Accession No. UniGene ID Ensembl Gene ID coagulation factor XIII, A1 polypeptide F13A1 Human This gene encodes the coagulation
More informationElena BM Breidenstein, PhD 21 April 2018
Discovery of a Novel Oral Antibiotic, DDS-01 (SMT-571), to Treat Multi-Drug Resistant Neisseria gonorrhoeae Enabled by a Proprietary Transposon Technology Elena BM Breidenstein, PhD 21 April 2018 Forward-Looking
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationThe 2012 PRG study: Assessing longitudinal variability in routine peptide LC-MS/MS analysis
The 2012 PRG study: Assessing longitudinal variability in routine peptide LC-MS/MS analysis Thanks! 2012 PRG Maureen K. Bunger (Chair) - North Carolina Central University Tracy M Andacht - Centers for
More information